{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T01:45:15Z","timestamp":1782438315045,"version":"3.54.5"},"reference-count":47,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.cld.2025.06.008","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T03:44:20Z","timestamp":1753847060000},"page":"641-655","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Recent Advances in Primary Biliary Cholangitis Treatment"],"prefix":"10.1016","volume":"29","author":[{"given":"Taranika Sarkar","family":"Das","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Vuppalanchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cld.2025.06.008_bib1","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jhep.2022.05.011","article-title":"EASL clinical practice guidelines on sclerosing cholangitis","volume":"77","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2025.06.008_bib2","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/hep.32117","article-title":"Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases","volume":"75","author":"Lindor","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2025.06.008_bib3","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s13023-024-03086-0","article-title":"Epidemiology of autoimmune liver disease in Korea: evidence from a nationwide real-world database","volume":"19","author":"Lim","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.cld.2025.06.008_bib4","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1136\/gutjnl-2020-322362","article-title":"Recent advances in clinical practice: epidemiology of autoimmune liver diseases","volume":"70","author":"Trivedi","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.cld.2025.06.008_bib5","article-title":"Past, current, and future trends in the prevalence of primary sclerosing cholangitis and inflammatory bowel disease across England (2015-2027): a nationwide, population-based study","volume":"44","author":"Crothers","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.cld.2025.06.008_bib6","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.cld.2022.06.001","article-title":"Contemporary epidemiology of primary biliary cholangitis","volume":"26","author":"Colapietro","year":"2022","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.cld.2025.06.008_bib7","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/hep.32771","article-title":"AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma","volume":"77","author":"Bowlus","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2025.06.008_bib8","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.cld.2022.06.004","article-title":"Autoantibodies in primary biliary cholangitis","volume":"26","author":"Leung","year":"2022","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.cld.2025.06.008_bib9","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.cld.2022.06.003","article-title":"Immunologic responses and the pathophysiology of primary biliary cholangitis","volume":"26","author":"Chen","year":"2022","journal-title":"Clin Liver Dis"},{"issue":"7","key":"10.1016\/j.cld.2025.06.008_bib10","doi-asserted-by":"crossref","DOI":"10.1111\/eci.70041","article-title":"Fatigue and itch severity in patients with PBC and PSC: Prospective analysis of two large cohorts","volume":"55","author":"Kruk","year":"2025","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.cld.2025.06.008_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2025.102565","article-title":"Unmet needs in autoimmune liver diseases","volume":"95","author":"Kolev","year":"2025","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.cld.2025.06.008_bib12","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1007\/s10620-023-07862-z","article-title":"Cholestatic pruritus treatments in primary biliary cholangitis and primary sclerosing cholangitis: a systematic literature review","volume":"68","author":"Smith","year":"2023","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cld.2025.06.008_bib13","doi-asserted-by":"crossref","first-page":"50","DOI":"10.23736\/S2724-5895.20.02792-0","article-title":"Health-related quality of life and symptoms in autoimmune liver diseases","volume":"69","author":"Janik","year":"2023","journal-title":"Minerva Gastroenterol"},{"key":"10.1016\/j.cld.2025.06.008_bib15","article-title":"Crosstalk between bile acids and intestinal epithelium: multidimensional roles of farnesoid X receptor and takeda G protein receptor 5","volume":"26","author":"Lin","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cld.2025.06.008_bib16","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/joim.13767","article-title":"Targeting the FGF19-FGFR4 pathway for cholestatic, metabolic, and cancerous diseases","volume":"295","author":"Li","year":"2024","journal-title":"J Intern Med"},{"key":"10.1016\/j.cld.2025.06.008_bib17","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.gastha.2023.09.013","article-title":"Farnesoid X receptor agonists: a promising therapeutic strategy for gastrointestinal diseases","volume":"3","author":"Almeqdadi","year":"2024","journal-title":"Gastro Hep Adv"},{"key":"10.1016\/j.cld.2025.06.008_bib18","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nrgastro.2013.151","article-title":"Bile acid receptors as targets for drug development","volume":"11","author":"Schaap","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2025.06.008_bib19","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1136\/gut.2010.233304","article-title":"FXR activation inhibits inflammation and preserves the intestinal barrier in IBD","volume":"60","author":"Wildenberg","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.cld.2025.06.008_bib20","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/MOG.0000000000000997","article-title":"Targeting bile salt homeostasis in biliary diseases","volume":"40","author":"Trampert","year":"2024","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.cld.2025.06.008_bib21","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000612","article-title":"PPAR agonists for the treatment of cholestatic liver diseases: over a decade of clinical progress","volume":"9","author":"Hayes","year":"2025","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.cld.2025.06.008_bib22","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/bcpt.13971","article-title":"The role of peroxisome proliferator-activated receptors in the regulation of bile acid metabolism","volume":"134","author":"Sun","year":"2024","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.cld.2025.06.008_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/cells13151296","article-title":"PPAR-mediated bile acid glucuronidation: therapeutic targets for the treatment of cholestatic liver diseases","volume":"13","author":"Gallucci","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.cld.2025.06.008_bib24","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41569-021-00569-6","article-title":"PPAR control of metabolism and cardiovascular functions","volume":"18","author":"Montaigne","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.cld.2025.06.008_bib25","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41392-024-01811-6","article-title":"Bile acid metabolism and signaling in health and disease: molecular mechanisms and therapeutic targets","volume":"9","author":"Fleishman","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.cld.2025.06.008_bib26","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.14309\/ajg.0000000000002128","article-title":"Ursodeoxycholic acid treatment-induced GLOBE score changes are associated with liver transplantation-free survival in patients with primary biliary cholangitis","volume":"118","author":"de Veer","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2025.06.008_bib27","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy","volume":"149","author":"Lammers","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2025.06.008_bib28","article-title":"Primary biliary cholangitis: personalizing second-line therapies","author":"Levy","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2025.06.008_bib29","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1053\/j.gastro.2022.08.054","article-title":"Greater transplant-free survival in patients receiving obeticholic acid for primary biliary cholangitis in a clinical trial setting compared to real-world external controls","volume":"163","author":"Murillo Perez","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2025.06.008_bib30","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2306185","article-title":"Efficacy and safety of elafibranor in primary biliary cholangitis","volume":"390","author":"Kowdley","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cld.2025.06.008_bib31","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2312100","article-title":"A phase 3 trial of seladelpar in primary biliary cholangitis","volume":"390","author":"Hirschfield","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cld.2025.06.008_bib33","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S2468-1253(17)30246-7","article-title":"Seladelpar (MBX-8025), a selective PPAR-delta agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study","volume":"2","author":"Jones","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2025.06.008_bib34","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jhep.2021.08.025","article-title":"Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis","volume":"76","author":"Vuppalanchi","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2025.06.008_bib35","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid","volume":"148","author":"Hirschfield","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2025.06.008_bib40","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/cpt.3450","article-title":"Pharmacokinetic, safety, and pharmacodynamic profiles of saroglitazar magnesium in cholestatic cirrhosis with hepatic impairment and participants with renal impairment","volume":"117","author":"Vuppalanchi","year":"2025","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cld.2025.06.008_bib41","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/liv.15596","article-title":"Setanaxib, a first-in-class selective NADPH oxidase 1\/4 inhibitor for primary biliary cholangitis: a randomized, placebo-controlled, phase 2 trial","volume":"43","author":"Invernizzi","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.cld.2025.06.008_bib42","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1016\/S0618-8278(19)30002-7","article-title":"Efficacy of GKT831 in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid: interim efficacy results of a phase 2 clinical trial","volume":"70","author":"Dalekos","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2025.06.008_bib43","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.cgh.2023.02.005","article-title":"New treatment paradigms in primary biliary cholangitis","volume":"21","author":"Levy","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2025.06.008_bib45","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cld.2025.06.008_bib46","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.14309\/01.ajg.0001028820.02913.42","article-title":"Combined effect of obeticholic acid and bezafibrate in patients with primary biliary cholangitis and inadequate response or intolerance to ursodeoxycholic acid: 6-month results from a phase 2 trial","volume":"119","author":"Ballard","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2025.06.008_bib47","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1016\/S0168-8278(24)00594-4","article-title":"Combined effect of obeticholic acid and bezafibrate in patients with primary biliary cholangitis and inadequate response or intolerance to ursodeoxycholic acid: 6-month results from a phase 2 trial","volume":"80","author":"Jones","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2025.06.008_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2022.100544","article-title":"Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis","volume":"4","author":"Schramm","year":"2022","journal-title":"Jhep Reports"},{"key":"10.1016\/j.cld.2025.06.008_bib49","doi-asserted-by":"crossref","first-page":"S480","DOI":"10.1016\/S0168-8278(20)31439-2","article-title":"Correlation of serum bile acids and pruritus with aldafermin (NGM282) therapy in patients with primary sclerosing cholangitis","volume":"73","author":"Mayo","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2025.06.008_bib50","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jhep.2018.10.035","article-title":"Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial","volume":"70","author":"Hirschfield","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2025.06.008_bib51","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/hep4.1209","article-title":"NGM282 for treatment of patients with primary biliary cholangitis: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"2","author":"Mayo","year":"2018","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.cld.2025.06.008_bib52","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jhep.2020.09.011","article-title":"A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA","volume":"74","author":"Hirschfield","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2025.06.008_bib53","doi-asserted-by":"crossref","first-page":"465","DOI":"10.4049\/jimmunol.2200208","article-title":"Tolerogenic immune-modifying nanoparticles encapsulating multiple recombinant pancreatic beta cell proteins prevent onset and progression of type 1 diabetes in nonobese diabetic mice","volume":"209","author":"Podojil","year":"2022","journal-title":"J Immunol"},{"key":"10.1016\/j.cld.2025.06.008_bib54","unstructured":"Molly Frey CB, Adam Elhofy, Samantha Genardi, et al. Tolerogenic treatment with CNP-104 results in regulation TH17 cells slowing progression of PBC on liver stiffness. 2024."}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326125000480?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326125000480?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T06:25:29Z","timestamp":1760855129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326125000480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1089326125000480"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2025.06.008","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent Advances in Primary Biliary Cholangitis Treatment","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2025.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}